In this issue:
Efficacy of nusinersen in early-onset SMA
Newborn screening for SMA in Australia
Oral risdiplam in infants with type 1 SMA
Clinical phenotype of patients with four SMN2 copies
Four-year follow-up of patients with type 1 SMA treated with nusinersen
Depression, anxiety, and sleep quality of caregivers of children with SMA
Effects of gene replacement therapy on respiratory outcomes in children with SMA
Are total tau levels in CSF a biomarker for nusinersen treatment response?
Nusinersen improves diaphragmatic motility in adults with SMA
Continued benefit of nusinersen after initiation in the presymptomatic stage
Please login below to download this issue (PDF)